Cargando…

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials

BACKGROUND: As one of the novel therapeutic drugs that targets Calcitonin gene-related peptide (CGRP), 75 mg rimegepant has been used for the acute management of migraine, which is one of the most common neurological diseases worldwide. Several clinical trials have been conducted to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Bixi, Yang, Yanbo, Wang, Zilan, Sun, Yue, Chen, Zhouqing, Zhu, Yun, Wang, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992660/ https://www.ncbi.nlm.nih.gov/pubmed/32038251 http://dx.doi.org/10.3389/fphar.2019.01577

Ejemplares similares

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
por: Yang, Yanbo, et al.
Publicado: (2020)

Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
por: Gao, Bixi, et al.
Publicado: (2020)

Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials
por: Wang, Qinghui, et al.
Publicado: (2023)

Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Sun, Yue, et al.
Publicado: (2020)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Antagonism of CGRP Signaling by Rimegepant at Two Receptors
por: Pan, Kylie S., et al.
Publicado: (2020)

Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023)

Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wu, Xin, et al.
Publicado: (2021)

A new scoring system for predicting extent of resection in medial sphenoid wing meningiomas based on three-dimensional multimodality fusion imaging
por: Wang, Zilan, et al.
Publicado: (2020)

COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management
por: Wang, Zilan, et al.
Publicado: (2020)

Efficacy and safety of stereotactic body radiotherapy for painful bone metastases: Evidence from randomized controlled trials
por: Wang, Zilan, et al.
Publicado: (2022)

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
por: Johnston, Karissa M., et al.
Publicado: (2021)

Intraoperative indocyanine green video angiography (ICG–VA) with FLOW 800 software in complex intracranial aneurysm surgery
por: Xue, Tao, et al.
Publicado: (2021)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials
por: Xue, Tao, et al.
Publicado: (2020)

Is the right way to go in between?: Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant—post hoc results from an open label safety study (BHV3000–201)
por: Gantenbein, Andreas R., et al.
Publicado: (2023)

Efficacy and safety of recanalization therapy for acute ischemic stroke with COVID-19: A systematic review and meta-analysis
por: Wang, Zilan, et al.
Publicado: (2022)

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
por: Tao, Xinyu, et al.
Publicado: (2022)

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
por: Johnston, Karissa, et al.
Publicado: (2022)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis
por: Yang, Yanbo, et al.
Publicado: (2022)

Efficacy and safety of Chinese herbal medicine for atopic dermatitis: Evidence from eight high-quality randomized placebo-controlled trials
por: Cai, Xiaoce, et al.
Publicado: (2022)

Efficacy and Safety of Qinghao Biejia Decoction in the Treatment of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
por: Li, Xiaobo, et al.
Publicado: (2021)

Efficacy and Safety of Xueshuantong Injection on Acute Cerebral Infarction: Clinical Evidence and GRADE Assessment
por: Lyu, Jian, et al.
Publicado: (2020)

Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
por: Powell, Lauren C., et al.
Publicado: (2022)

Modifiable factors for migraine prophylaxis: A mendelian randomization analysis
por: Zheng, Hui, et al.
Publicado: (2023)

Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis
por: Song, Zhaoming, et al.
Publicado: (2022)

Efficacy and safety of traditional Chinese medicine adjuvant therapy for severe pneumonia: evidence mapping of the randomized controlled trials, systematic reviews, and meta-analyses
por: Xie, Kai, et al.
Publicado: (2023)

Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis
por: Chen, Huiru, et al.
Publicado: (2023)

Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
por: Wang, Xing, et al.
Publicado: (2021)

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
por: Zou, Rongrong, et al.
Publicado: (2022)

Use of Rimegepant in the Management of Cervicogenic Headache Secondary to Trauma: A Case Series
por: Zaw, Shin T, et al.
Publicado: (2023)

Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial
por: Liu, Yayun, et al.
Publicado: (2023)

Efficacy and safety of sonothombolysis versus non-sonothombolysis in patients with acute ischemic stroke: A meta-analysis of randomized controlled trials
por: Chen, Zhouqing, et al.
Publicado: (2019)

Efficacy and safety of Panax notoginseng saponins (Xuesaitong) for patients with acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials
por: Shi, Xinyi, et al.
Publicado: (2023)

Efficacy and safety of remote ischemic conditioning for acute ischemic stroke: A comprehensive meta‐analysis from randomized controlled trials
por: Kan, Xiuji, et al.
Publicado: (2023)

Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms
por: Zhang, Shuo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1edhtkm9llj47bde913gbmi75l